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Background: There is no consensus regarding the management of ovarian cancer patients, who have shown
complete clinical response (CCR) to primary therapy and have rising cancer antigen CA-125 levels but have no
symptoms of recurrent disease. The present study aims to determine whether follow-up CA-125 levels can be used
to identify the need for imaging studies and secondary cytoreductive surgery (CRS).
Methods: We identified 410 ovarian cancer patients treated at The University of Texas MD Anderson Cancer Center
between 1984 and 2011. These patients had shown CCR to primary therapy. Follow-up was conducted based on
the surveillance protocol of the MD Anderson Cancer Center. We used the Cox proportional hazards model and
log-rank test to assess the associations between the follow-up CA-125 levels and secondary CRS and survival
duration.
Results: The CA-125 level of 1.68 × nadir was defined as the indicator of recurrent disease (p < 0.001). The specificity
and sensitivity of this criterion were 82.9% and 85.6%, respectively, and the median lead-time of the CA-125
biochemical progression prior to clinically-defined relapse was 31 days (ranging from 1 to 391 days). The median
number of the negative imaging studies for the clinical relapse findings in patients with a CA-125 level of < 1.68 × nadir
was 3 (ranging from 0 to 24 times). The increase of CA-125 level at relapse was an independent predictor of overall and
progression free survival in patients who had shown CCR to primary therapy (p = 0.04 and 0.02 respectively). The overall
and progression free survival durations in patients with a CA-125 level≤ 1.68 × nadir at relapse (69.4 and 13.8 months)
were longer than those with a CA-125 level > 1.68 × nadir at relapse (55.7 and 10.4 months; p = 0.04 and 0.01,
respectively). The overall and progression free survival duration of patients with asymptomatic relapse and underwent a
secondary CRS was longer than that of patients with symptomatic relapse (p = 0.02 and 0.04 respectively).
Conclusions: The increase of serum CA-125 levels is an early warning of clinical relapse in ovarian cancer. Using CA-125
levels in guiding the treatment of patients with asymptomatic recurrent ovarian cancer, who have shown CCR to
primary therapy, can facilitate optimal secondary CRS and extend the survival duration of the patients.
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Epithelial ovarian cancer (EOC) is the most lethal gyneco-
logic malignancy in the United States [1]. Although pri-
mary therapy results in a complete clinical response (CCR)
in more than 50% of EOC patients, achieving complete
cure is rare. In fact, 3 out of 4 EOC patients develop recur-
rent disease within 2 years and ultimately die from the dis-
ease within 5 years [2]. The early detection and treatment
of recurrent EOC improves the survival outcome of
patients; however, the absence of effective follow-up enab-
ling early detection and treatment remains a clinical chal-
lenge. Moreover, there is no agreement regarding the
characteristics that indicate recurrence, the surveillance
interval, and the necessary means of follow-up [3-6]. Unlike
many other recurrent solid tumors, which have macro-
scopic masses, a significant proportion of recurrent EOC
presents as immeasurable micro-nodular lesions and ascites
that are widespread and diffused; therefore, quantifying
recurrence in time is as difficult as seeking effective therapy
in EOC patients.
The CA-125 antigen is a serum marker first identified
by Bast et al. and developed through the immunization of
mice by a monoclonal antibody (OC125), using an ovarian
cancer cell line in 1981. Since then, CA-125 has been va-
lidated as an effective marker for monitoring EOC [7].
Rustin et al. posited that the criterion for tumor progres-
sion in the detection of recurrent EOC is a CA-125 level
of 2 × the upper limit of normal (ULN), which has a sensi-
tivity and specificity of 88% and 98%, respectively. This
CA-125 threshold is accepted by the Gynecologic Cancer
InterGroup [8-12]. Only one randomized trial has been
conducted to investigate the value of routinely measuring
follow-up CA-125 levels in EOC patients. In the MRC
OV05/EORTC 55955 trial, Rustin et al. suggested that re-
introducing chemotherapy in patients who have shown
signs of biochemical recurrence of the disease does not im-
prove survival duration, and that patients should not
undergo regular CA-125 measurements if they have no
symptoms suggesting relapse [13]. The value of routine
CA-125 follow-up was thus denied. However, this trial did
not rule out the possibility of using CA-125 levels to guide
the early detection of clinically recurrent EOC, which can
benefit from the earlier administration of secondary cytore-
ductive surgery (CRS) [14].
Secondary CRS is another major treatment for recur-
rent EOC. The DESKTOP I and II trials identified three
independent factors for indicating complete resection,
namely, good performance status, complete resection at
primary surgery, and the absence of ascites. Complete
resection when all three factors are present reached 79%
in the DESKTOP I trail and 76% in the DESKTOP II
trail [15,16]. The prospective DESKTOP III study on this
issue is ongoing. Identifying the appropriate patients for
the potentially morbidity-inducing procedure remains aclinical challenge. Hence, the possibility of utilizing rising
CA-125 levels to optimize the secondary CRS in asymp-
tomatic EOC patients with recurrent disease remains
uncertain.
Prior to the appearance of a measurable disease on im-
aging studies, CA-125 levels rise a median of 4 months in
approximately 70% of EOC patients who develop a recur-
rent disease [11,17]. The criterion used to define EOC re-
currence has remained relatively stable over the past
20 years; in comparison, the density resolution technology
in medical imaging has improved significantly [18-20].
The widespread use of higher-resolution Computed Tom-
ography (CT), Magnetic Resonance Imaging (MRI), and
Positron Emission Tomography-Computed Tomography
(PET-CT) has resulted in the more timely and accurate
detection of smaller lesions. The use of sensitivity, specifi-
city, and lead-times attained using a CA-125 level of 2 ×
ULN as part of the criterion in defining recurrent disease
in EOC patients was formulated using radiological tech-
nology nearly two decades ago. However, the relevance of
such criterion remains uncertain.
In the present study, we retrospectively evaluated EOC
patients who achieved CCR through primary therapy
without undergoing consolidation and maintenance ther-
apies. The CA-125 levels recorded after completing pri-
mary therapy were used as indicators of clinical relapse.
The overall survival (OS) and progression free survival
(PFS) of patients receiving secondary CRS, as indicated by
the CA-125 levels or the relapse-related symptoms, were
analyzed. Our data revealed the value of CA-125 follow-
up in patients with the opportunity for further surgery.Methods
Study population
This retrospective study was approved by the Institutional
Review Board of MD Anderson. We identified 410 EOC
patients who achieved CCR following primary treatment
at MD Anderson from clinical stations between January 1,
1984 and February 14, 2011. Those who did not receive
the standard primary treatment and achieved CCR were
excluded. When the patients completed primary therapy,
follow-up was conducted based on the routine follow-up
protocol for EOC of MD Anderson, which included
follow-up visits every 3 months for the first 2 years, every
4 months in year 3, and every 6 months in years 4 and 5.
The patients underwent medical history investigation, phys-
ical examination, and CA-125 tests at each follow-up visit.
Imaging studies (i.e., ultrasonography, MRI, or area-specific
CT or x-ray) were performed in all patients at the first
follow-up visit; thereafter, imaging studies were performed
only in patients whose clinical examinations suggested re-
current cancer. The Response Evaluation Criteria in Solid
Tumors (RECIST) and the World Health Organization
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and clinical relapse [21-23].
We evaluated the clinicopathological data of all
patients, including the histological type and grade of the
tumor [24,25], stage of the disease as defined by the
International Federation of Gynecology and Obstetrics
[26], type of primary treatment received, volume of asci-
tes, time of recurrent disease diagnosis, management of
recurrent disease, and date of death or last follow-up.
The OS duration was defined as the time beginning
from the diagnosis of EOC to death or last follow-up.
PFS was the length of time after treatment during which
patients being treated does not get worse. Pathological
diagnoses of recurrent EOC were reviewed at the time
of diagnosis by two MD Anderson pathologists, namely,
J. Liu and J. Zhang.
Definition of clinical response and CA-125 analysis
In the current study, CCR was achieved when the follow-
ing criteria were met: the absence of tumor-associated clin-
ical symptoms, signs of residual tumor on the physical
examination and EOC-negative imaging study results, and
a serum CA-125 concentration below the ULN. Clinical re-
lapse was identified with the occurrence of any new meas-
urable lesion, as revealed through imaging studies or
clinical examination [22]. Biochemical relapse was assessed
using CA-125 levels and then identified based on the re-
ceiver operating characteristic (ROC) curve.
Next, we reviewed the serum CA-125 concentrations
recorded from the end of primary therapy to death or last
follow-up. The serum CA-125 concentrations were deter-
mined using a commercially available Roche immunoassay.
In order to determine the nadir CA-125 levels of individual
patients, we included the CA-125 levels recorded in the
2 weeks following the first follow-up evaluation after the
completion of primary therapy. The CA-125 recorded at
relapse included those recorded in the 2 weeks following
the confirmation of imaging-defined recurrent EOC. The
apex of the follow-up CA-125 level was defined as the
highest CA-125 level whose measurement can be con-
firmed (i.e., repeated with < 25% variation in the result)
within 3 months in EOC patients without recurrent dis-
ease. Tumor-associated symptomatic relapse was
defined as the recurrence of the disease after returning to
MD Anderson for unscheduled follow-up visits were con-
sidered to have tumor-associated symptoms. Secondary
CRS as a selective procedure was performed in 84
Platinum-sensitive EOC patients (generally referring to the
progression of the free interval of at least 6 months from
the completion of primary therapy) with good performance
status and intended purpose of tumor reduction. Optimal
cytoreduction was defined as the threshold of ≤ 1 cm of the
residual tumor, and suboptimal debulking was determined
as having more than 1 cm of nodules left.Statistical analysis
We used the Cox proportional hazards model to assess
the relationship between the CA-125 level as a continu-
ous variable and the OS and PFS. Step-wise regression
was conducted to build the multivariate models. The
log-rank test was used to assess this relationship as a di-
chotomous variable around the median value. We also
calculated the ROC curve, which was placed over the
data points to form a smoothed curve using a regression
model. Next, we performed the Z-test to determine
whether the sensitivity and/or specificity of one modality
were significantly different from that of the others. The
p values < 0.05 were considered statistically significant.
All analyses were conducted using the SPSS statistical
software program (version 18.0; SSPS Inc, Chicago, IL).
Results
Patient characteristics
The clinicopathological characteristics of the patients
are given in Table 1. Of the 410 EOC patients included
in the present study, 361 (88.0%) and 49 (12.0%) patients
had high-grade and low-grade primary tumors, respect-
ively. Most patients (317; 77.3%) had serous carcinoma.
The patients who were alive at the time of our analysis
had a median follow-up time of 38 months (interquartile
range, 20.4 months to 73.2 months). The median OS dur-
ation of all the patients was 72.1 months (95% confidence
interval [CI], 63.4 months to 80.8 months). The median
CA-125 level at relapse (53 U/ml; range, 6 U/ml to 3372
U/ml) was significantly higher than that of the median
pre-relapse highest CA-125 level (11 U/ml; range, 5 U/ml
to 87 U/ml; p < 0.001; Figure 1). The patients who were
symptomatic at recurrence reported experiencing pain
(8 patients), gastrointestinal dysfunction (26 patients), and/
or mass effect (13 patients) and underwent secondary CRS.
Prediction of clinical relapse using follow-up CA-125 level
To predict clinical relapse, we used the ROC curve to
analyze the highest CA-125 levels during the follow-up
sessions in patients who did not have recurrence and
had relapse (p < 0.001). The sensitivity and the specificity
for predicting clinical relapse were 82.9% and 85.6%, re-
spectively, which were identified using a CA-125 level of
1.68 × nadir as the cut-off point (Figure 2A).
Of the 193 patients who had clinical recurrence, 111
(57.5%) had an increased CA-125 level to 1.68 × nadir be-
fore clinical recurrence; the median lead-time in these
patients was 31 days (range, 1 to 391 days). Of the 106
patients who had shown biochemistry relapse, 42 (39.6%)
had an increased CA-125 level to 2 × ULN before clinical
recurrence; the median lead-time in these patients was
16 days (range, 1 to 250 days). When the CA-125 level
was at 2 × the ULN, the sensitivity and specificity for pre-
dicting clinical relapse were 36.9% and 98.4% respectively.
Table 1 Patient characteristics of the present study
population
Characteristic No. of patients (%)
Median age, years (range) 58.6 (23.5–89.2)
Median CA-125 level at diagnosis, U/ml (range) 490.5 (7–33439)






















Residual disease after primary surgery
Optimal (≤ 1 cm) 322






Note: All data are no. of patients (%) unless noted otherwise.
Abbreviations: MMMT, malignant mixed müllerian tumor; FIGO, International
Federation of Gynecology and Obstetrics; NACT, Neoadjuvant chemotherapy.
*5 Chinese, 4 Middle Eastern, 1 Japanese, 1 Korean, and 2 Indian patients.
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68 days, Table 2) when the CA-125 level increased from
1.68 × nadir to 2 × the ULN.
On average, the patients underwent imaging checks
(CT, MRI, and/or PET-CT) thrice (range, 0 to 24 imaging
studies) before clinical relapse. The median CA-125 meas-
urement time was 16 (range, 0 to 52 measurements) at
the same periods.Determining the association of CA-125 level with tumor
size and optimal secondary CRS
The median longest tumor diameter at relapse was 2.1 cm
(range, < 1 cm to 14 cm), and the median area of the
tumor at relapse was 5.3 cm2 (range, < 1 cm2 to 144 cm2);
these were obtained through imaging assays. There were
no correlations between CA-125 level on the one hand
and the longest diameter of the tumor based on RECIST
(p = 0.21) and the tumor area based on the WHO criteria
(p = 0.35) on the other hand. Likewise, pre-surgery CA-125
level (p = 0.21) was not associated with optimal secondary
CRS (Figure 2B).
Identifying CA-125 level and secondary CRS as
independent survival indicators
Cox proportional hazards model revealed that the in-
crease of CA-125 level at relapse were independent OS
and PFS predictors of recurrent EOC (p = 0.04 and 0.02
respectively; Table 3).
The median OS and PFS durations of patients with a
serum CA-125 concentration of ≤ 1.68 × nadir at relapse
(69.4 and 13.8 months, respectively) were significantly
longer than those of patients with a serum CA-125 level
of > 1.68 × nadir at relapse (55.7 and 10.4 months; p = 0.04
and 0.01 respectively; Figure 3A and B). Multivariate ana-
lyses revealed that secondary CRS was an independent
predictor of OS and PFS (p = 0.02 and p = 0.01 respect-
ively; Table 3). The OS durations of patients who under-
went secondary and optimal CRS were longer than those
of patients who did not undergo or had suboptimal sur-
gery (p = 0.01 and p = 0.04 respectively; Additional file 1:
Figure S1A and B), Likewise, the PFS durations (p = 0.01
and p = 0.02 respectively; Additional file 2: Figure S2A
and B). Asymptomatic patients in whom the recurrent
disease was defined through a CA-125 level had a higher
optimal secondary CRS rate (92.2% vs 43.5%) and longer
OS duration than the symptomatic patients (p = 0.02;
Figure 4A). The PFS duration of the patients who under-
went optimal secondary CRS for the asymptomatic recur-
rent patients was significantly longer than that of the
symptomatic recurrent cases (p = 0.04; Figure 4B).
Discussion
The mean 5-year survival rate following the diagnosis of
recurrent EOC is less than 10%. The management of re-
current diseases is a key aspect in the overall therapeutic
management of patients with EOC. In addition to deter-
mining the most appropriate treatment for the primary
disease, defining the triggers that signify the need for initi-
ating or changing therapy at relapse is important in ensur-
ing effective management [27,28]. The findings of the
present study were focused on the use of CA-125 levels to
guide the treatment of asymptomatic recurrent EOC
patients who had shown CCR to primary therapy. We
Figure 1 Serum CA-125 concentrations in patients who developed recurrent EOC (median, 53 U/ml; range, 6 U/ml to 3372 U/ml) were
significantly higher than the highest CA-125 level recorded during follow-up in patients who did not develop recurrent disease
(median, 11 U/ml; range, 5 U/ml to 87 U/ml; p < 0.001).
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ondary CRS and extend the OS durations of patients.
Many previous studies on this topic ignored secondary
CRS, which is one of the major treatment choices apart
from chemotherapy in selected cases. A previous study
revealed that tumor burden was an independent factor
associated with therapy response and survival [29]. Regu-
lar follow-up once a patient who has undergone standard
primary treatment has achieved CCR is warranted, be-
cause a patient who develops recurrent EOC can benefit
from being treated without delay when their tumors are
comparatively small.
The MRC OV05/EORTC 55955 trial showed contrast-
ing results with those that reported that the earlier initi-
ation of second-line chemotherapy for recurrent EOC
patients can improve their outcomes as testified by some
other studies [30,31]. Secondary CRS has also been con-
sidered to be appropriate for patients with a low-volume
disease or isolated lesions. Some retrospective studies
have suggested that select patients who undergo optimalFigure 2 ROC curve for tumor relapse (A) and optimal secondary CRSsecondary CRS have better PFS and OS duration than
those who do not undergo therapy [14,32,33].
Several factors influence whether recurrent lesions can
be optimally resected, including the number and size of
the tumors, the presence of ascites and/or carcinomatosis,
and progression-free interval. CA-125 levels can help to
recruit populations for secondary debulking. Fleming et al.
showed that a shorter interval between the CA-125 eleva-
tion and the secondary CRS correlates with a greater inci-
dence of optimal resection, thus leading to a longer
median OS duration (47 months) than that of longer inter-
val cases (23 months) [32]. They also found that the sec-
ondary CRS was delayed every week in the 16.4 weeks
following the first elevation in CA-125 level; furthermore,
the likelihood that the resection would be complete
decreased by 3%. Frederick et al. proposed that a pre-
operative CA-125 level of < 250 U/ml can predict surgical
success leading to prolonged survival [34]. In the present
study, we found that the CA-125 level-guided asymptom-
atic recurrent EOCs have higher secondary CRS rates and(B) by CA-125 level.
Table 2 Relapse prediction using the rising values of serum CA-125 levels from nadir to ≥ 1.68 × nadir or to ≥ 70 U/ml
Variable 1.68 × Nadir 70 U/ml
CT MRI PET–CT
True positive, no. of patients 170 6 14 90
False positive, no. of patients 11 0 2 2
True negative, no. of patients 115 6 2 124
False negative, no. of patients 74 3 8 154
Sensitivity, % 69.7 66.6 63.6 36.9
Specificity, % 88.5 100 50.0 98.4
Positive predictive value, % 93.9 100 87.5 97.8
Negative predictive value, % 60.8 66.6 20.0 44.6
Median lead-time, days (range) 31 (1–391) 16 (1–250)
Median lead-time from 2 × nadir to 70 U/ml, days (range) 22 (0–46)
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography.
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determined relapse.
Recurrent EOC, unlike other solid tumors, tends to
present without accompanying symptoms and forms mul-
tiple small implantations, particularly in the small intestine
and mesentery, which cannot be readily detected using
conventional imaging examinations [35,36]. The RECIST
and WHO criteria for recurrent EOC focus on detectable
changes in tumor size rather than the metastatic character-
istics of the disease. However, imaging study results may
not accurately reflect disease progression, because the
microlesions are difficult to detect using such studies. The
CA-125 level is an alternative indicator of tumor relapse,
and is a surrogate of imaging study-defined relapse. The
GCIG criterion is initially effective in identifying asymp-
tomatic patients with recurrent EOC with sufficient
sensitivity and an extremely low false positive rate (specifi-
city > 97%) while avoiding the unnecessary treatment of










Primary CRS 1.06 0.5
Secondary CRS 1.41 1.0
Ascites 1.79 1.0
Relapse/Nadir CA-125 level 1.00 1.0
Abbreviations: HR, hazard ratio; CI, confidence interval; FIGO, International Federatiosensitivity of these biochemical relapse criteria has since
decreased to 36.9%. The resolutions attainable through im-
aging systems have improved dramatically over the past
two decades. Imaging-based relapse criteria are confounded
by the use of low- or high-density resolution imaging stud-
ies to detect smaller lesions [37]. Other imaging technolo-
gies, such as PET-CT, dynamic contrast-enhanced MRI,
diffusion-weighted MRI and perfusion CT, have further ele-
vated the resolution efficiency, accurately detecting the
presence of microlesions. The combination of image-
guided biopsy and a lower CA-125 level can be used to de-
tect microlesions. In the present study, the sensitivity
attained using a CA-125 level of 1.68 × nadir was relatively
high (85.6%).
Ovarian cancer patients who have CCR to primary ther-
apy are not a homogenous group. The nadir CA-125 level
is a factor in determining patient prognosis. A slight in-
crease in the CA-125 levels within the normal range at the
end of primary treatment is inversely associated with thatical characteristics by multivariate analysis in recurrent
Progression free survival










n of Gynecology and Obstetrics; CRS, cytoreductive surgery.
Figure 3 OS (A) and PFS (B) durations were shorter in patients with a CA-125 level of > 1.68 × nadir at relapse than those in patients
with a CA-125 level of ≤ 1.68 × nadir at relapse.
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which the CA-125 levels increased from different individ-
ual nadir value to 2 × ULN was significantly different. The
comparison between the threshold CA-125 level defined
by the GCIG and the absolute CA-125 values without tak-
ing individual nadir CA-125 levels is considered in our
criterion.
The continuous increase of CA-125 levels implies a con-
tinuous dominant course of tumor progression. Determin-
ing a CA-125 level at which the recurrent disease would
be distinguishable using imaging studies is important. In
the present study, this CA-125 value was determined on
the basis of its use in diagnosing recurrent EOC. In con-
trast to the data presented by previous studies, the poten-
tial cut-off CA-125 values have been tested using their
diagnostic performance and areas under the ROC curve.
An increase in CA-125 levels in an asymptomatic pa-
tient presents a dilemma. Some gynecologic oncologists
recommend a wait-and-see approach, but the duration
of the waiting period and how the patients should be
monitored are unclear. Asymptomatic patients waiting
for symptoms can experience significant anxiety and re-
port unspecific symptoms to their physicians, therebyFigure 4 Symptomatic patients who underwent secondary CRS had sresulting in unnecessary imaging examinations. Regular
CA-125 testing might also give rise to the psychosocial
impairments of the patients based on the possible rise of
CA-125 levels during their daily lives. A clear clinical
interventional point of the CA-125 level can thus help
patients overcome CA-125 addiction to a certain extent
only if they prefer to not know the specifics. Other gyne-
cologic oncologists argued that time and treatment
choices are lost from asymptomatic to symptomatic. A
CA-125 level of 1.68 × nadir in asymptomatic patients
undergoing a wait-and-see approach can be used as a
threshold at which specific imaging examinations be-
come warranted to avoid missing the opportunity to per-
form secondary CRS. However, our findings did not
reveal a relationship between the CA-125 levels at dis-
ease relapse and the imaging study-determined longest
diameters of tumors or tumor areas.
Given the selection bias inherent to non-blinded studies,
attempts to translate these favorable outcomes to all EOC
patients with recurrent disease should be approached with
caution. We recommend using a CA-125 level of 1.68 ×
nadir to indicate the need to initiate imaging studies in
detecting recurrent disease in EOC patients who had CCRhorter OS (A) and PFS (B) durations than asymptomatic patients.
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fewer instances of specious relapse and unnecessary im-
aging examinations. The ongoing DESKTOP III trial can
prospectively assess the role of secondary CRS in patients
with platinum-sensitive ovarian cancer. This important
trial should answer several key questions regarding the
management of recurrent EOC, including whether sec-
ondary CRS results in better outcomes than second-line
chemotherapy.
Additional files
Additional file 1: Figure S1. Patients who underwent secondary CRS
had longer OS durations than those who did not undergo secondary CRS
(A). Patients who underwent optimal secondary CRS had longer OS
durations than those who underwent suboptimal surgery (B).
Additional file 2: Figure S2. Patients who underwent secondary CRS
had longer PFS durations than those who did not undergo secondary
CRS (A). Patients who underwent optimal secondary CRS had longer PFS
durations than those who underwent suboptimal surgery (B).
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